theme for the 2010 American Society of Clinical Oncology (ASCO) annual meeting is “Advancing Quality through Innovation. and 3 in Clinical Science Symposium). The number of abstracts presented this year was increased compared to the last year meeting which had 96 abstracts in the field of gynecologic oncology. The key topics among them will be presented again in Best of ASCO? International. (Best of ASCO? is a conference where the 50 Best presentations made at ASCO will be presented by Members of the Scientific Committee. They will be presented and commented by different speakers.) Herein I’d like to introduce these abstracts to the readers briefly. Among these the most notable study was GOG 218 evaluating whether there is therapeutic impact from concurrent±maintenance bevacizumab (BEV) with standard chemotherapy (CP) in patients with stage III-IV epithelial Doramapimod ovarian cancer (EOC) primary peritoneal cancer (PPC) or fallopian cancer (FC).1 All women underwent abdominal surgery for staging and maximal tumor debulking before being randomly assigned to one of three treatment arms: 1) CP plus placebo during the induction phase (cycles 1 to 6) followed by placebo maintenance (cycles 7 to 22); 2) CP plus concurrent bevacizumab during induction followed by placebo maintenance; and 3) CP plus concurrent bevacizumab during induction followed by bevacizumab maintenance. Bevacizumab was not administered during the first 21-day induction cycle so as to limit postsurgical bleeding complications. The entire treatment schedule took 15 months to complete. Although overall survival was originally selected as the primary endpoint this was changed to progression-free survival (PFS) to accord with international consensus as a more appropriate endpoint for frontline phase III trials in this patient population as well as pressure by patients to unblind their treatment assignment in the event of disease progression. The investigators monitored disease progression based on radiographic evidence CA-125 measurements and global clinical deterioration. Overall survival safety and quality of life comprised the secondary endpoints. 1 873 patients were enrolled from US Canada South Korea Desmopressin Acetate and Japan between Sep 2005 and Jun 2009. Stage III optimally debulked (34%) stage III sub-optimally debulked (40%) and stage IV (26%) Doramapimod patients were similarly distributed in each treatment group. After a median follow-up of 17.4 months (range 0 to 50.7 months) PFS was significantly prolonged by 3.8 months in R3 group compared with R1 (14.1 months compared with 10.3 months respectively; hazard ratio [HR] 0.717 p<0.0001). No significant difference in PFS was observed between R2 and R1 (11.2 months compared with 10.3 months respectively; HR 0.908 p=0.080). At the time of analysis overall Doramapimod survival did not show any differences between the three arms; the survival data are not yet mature. The addition of BEV to CP appeared well tolerated. Although hypertension Doramapimod occurred significantly more often in the BEV arms compared with the control arm (p<0.05): Grade 3-4 hypertension was reported in 1.6% (R1) 5.4% (R2) and 10.0% (R3). The incidences of all other adverse events were similar across the arms. Gastrointestinal perforation events did not markedly increase with the use of BEV (2.6% to 2.8% in the BEV arms compared with 1.2% in the control arm). BEV as concurrent+maintenance regimen with standard CP is the first anti-angiogenic agent to demonstrate benefit (PFS) in advanced EOC primary peritoneal cancer or FC (abstr LBA1). This study was presented in the Plenary Session which includes the abstracts of practice-changing findings. Two abstracts in Oral Abstract Session will be reviewed in Best of ASCO?. One is about ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA).2 3238 postmenopausal women aged 50 to 74 with no significant family history of breast or ovarian cancer participated over an eight year period. It was prospective and multicenter screening study. Participants underwent a CA-125 blood test annually. Based on the ROCA result women were triaged to the next annual CA-125 (low risk) repeat CA-125 in 3 months (intermediate risk) or transvaginal sonography (TVS) and referral to a gynecologic oncologist (high risk). Based on clinical findings and TVS the gynecologic oncologist made the decision whether to proceed with surgery. The average.